Thorsten H Ecke1, Christian Arndt2, Carsten Stephan3, Steffen Hallmann4, Oliver Lux4, Thomas Otto2, Jürgen Ruttloff4, Holger Gerullis5. 1. HELIOS Hospital, Department of Urology, Bad Saarow, Germany thorsten.ecke@helios-kliniken.de. 2. Lukaskrankenhaus Neuss, Department of Urology, Neuss, Germany. 3. Department of Urology, Charité University Hospital, Berlin, Germany Berlin Institute for Urological Research, Berlin, Germany. 4. HELIOS Hospital, Department of Urology, Bad Saarow, Germany. 5. Lukaskrankenhaus Neuss, Department of Urology, Neuss, Germany School of Medicine and Health Sciences Carl von Ossietzky, University Oldenburg, Oldenburg, Germany.
Abstract
BACKGROUND/AIM: UBC Rapid is a test detecting fragments of cytokeratins 8 and 18 in urine. These are cytokeratins frequently overexpressed in tumor cells. We present the first results of a multi-centre study using UBC Rapid in patients with bladder cancer and healthy controls. MATERIALS AND METHODS: Clinical urine samples from 92 patients with tumors of the urinary bladder (45 low-grade and 47 high-grade tumors) and from 33 healthy controls were used. Urine samples were analyzed by the UBC Rapid point-of-care (POC) system and evaluated both visually and quantitatively using a concile Omega 100 POC reader. For visual evaluation, different thresholds of band intensity for considering a test as positive were applied. Sensitivities and specificities were calculated by contingency analyses. RESULTS: We found that pathological concentrations by UBC Rapid are detectable in urine of patients with bladder cancer. The calculated diagnostic sensitivity of UBC Rapid in urine was 68.1% for high-grade, but only 46.2% for low-grade tumors. The specificity was 90.9%. The area under the curve (AUC) after receiver-operated curve (ROC) analysis was 0.733. Pathological levels of UBC Rapid in urine are higher in patients with bladder cancer in comparison to the control group (p<0.0001). CONCLUSION: UBC rapid can differentiate between patients with bladder cancer and controls. Further studies with a greater number of patients will show how valuable these results are. Copyright
BACKGROUND/AIM: UBC Rapid is a test detecting fragments of cytokeratins 8 and 18 in urine. These are cytokeratins frequently overexpressed in tumor cells. We present the first results of a multi-centre study using UBC Rapid in patients with bladder cancer and healthy controls. MATERIALS AND METHODS: Clinical urine samples from 92 patients with tumors of the urinary bladder (45 low-grade and 47 high-grade tumors) and from 33 healthy controls were used. Urine samples were analyzed by the UBC Rapid point-of-care (POC) system and evaluated both visually and quantitatively using a concile Omega 100 POC reader. For visual evaluation, different thresholds of band intensity for considering a test as positive were applied. Sensitivities and specificities were calculated by contingency analyses. RESULTS: We found that pathological concentrations by UBC Rapid are detectable in urine of patients with bladder cancer. The calculated diagnostic sensitivity of UBC Rapid in urine was 68.1% for high-grade, but only 46.2% for low-grade tumors. The specificity was 90.9%. The area under the curve (AUC) after receiver-operated curve (ROC) analysis was 0.733. Pathological levels of UBC Rapid in urine are higher in patients with bladder cancer in comparison to the control group (p<0.0001). CONCLUSION:UBC rapid can differentiate between patients with bladder cancer and controls. Further studies with a greater number of patients will show how valuable these results are. Copyright
Authors: Jan Gleichenhagen; Christian Arndt; Swaantje Casjens; Carmen Meinig; Holger Gerullis; Irina Raiko; Thomas Brüning; Thorsten Ecke; Georg Johnen Journal: Int J Mol Sci Date: 2018-01-11 Impact factor: 5.923
Authors: Renate Pichler; Gennadi Tulchiner; Josef Fritz; Georg Schaefer; Wolfgang Horninger; Isabel Heidegger Journal: Int J Med Sci Date: 2017-07-19 Impact factor: 3.738
Authors: Jan Gleichenhagen; Christian Arndt; Swaantje Casjens; Carmen Töpfer; Holger Gerullis; Irina Raiko; Dirk Taeger; Thorsten Ecke; Thomas Brüning; Georg Johnen Journal: PLoS One Date: 2022-06-29 Impact factor: 3.752